NCT02809976

Topical Ruxolitinib for the Treatment of Vitiligo

Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Tufts Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.

Detailed description

The hypothesis is that JAK inhibitors can also successfully treat vitiligo. Lesional skin of both alopecia areata and vitiligo primarily contain T cells in a TH1 response as opposed to a mixed cell infiltrate such as in psoriasis or lichen planus. Both alopecia areata and vitiligo are TH1 mediated diseases dependent on the production of IFN-gamma to drive the response. CD8+ T cells are both necessary and sufficient for melanocyte destruction in vitiligo (van den Boorn JG et al 2009) and CD8+NKG2D+ T cells are also necessary and sufficient for hair loss in alopecia areata (Gilhar A et al 2013).

Conditions

• Vitiligo

Interventions

Type	Name	Description
DRUG	Ruxolitinib 1.5% Phosphate Cream	twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20

Timeline

• Start date: 2016-01-01
• Primary completion: 2017-01-01
• Completion: 2017-02-01
• First posted: 2016-06-22
• Last updated: 2020-08-31
• Results posted: 2020-08-31

Locations

1 site across 1 country: United States